Advinus Therepeutics announced that it has filed its first IND with the DCGI last week for a type 2 diabetes molecule and expects to commence phase 1 clinical trials shortly after approval.
Dr. Rashmi Barbhaiya, the CEO and Managing Director of the company stated, "Our drug discovery operations have now been expanded to almost 3 folds of what they were. The new facility will give us a lot of room for growth of internal programmes and innovative models for future partnerships. I am very proud that in less than 3 years we have been able to file our first IND for approval of clinical trials which is a combined effort of both our Pune and Bangalore operations."
Dr. Kasim Mookhtiar, Chief Scientific Officer of the company added, that "the filing of Advinus' first IND marks the beginning of the company's delivery of a pipeline of innovative products that addresses large unmet medical needs."
